Adventris Analysis: $500K Raised
What is Adventris?
Adventris Pharmaceuticals is a biotechnology company focused on cancer immunotherapy. The website does not list specific drug candidates, product names, or clinical-stage programs. No customer, partnership, funding, or certification details are visible on the homepage.
Location
212 27th Street, San Francisco, California 94131, United States
Employees
1-10
Founded
2022
Business Model
Biotechnology revenue from cancer immunotherapy, partnerships, and funding rounds.
Product Features & Capabilities
- cancer vaccines targeting specific mutations, first product focuses on lung cancer and KRAS mutation, aims to train the immune system to recognize and eliminate cancer cells, potential for annual vaccinations to prevent cancer deaths, off-the-shelf vaccine for KRAS mutation, annual pan-cancer vaccines for adults, training the immune system to recognize cancer mutations.
How much Adventris raised
Pre-Seed - $500,000
April 5, 2023Lead Investor: Y Combinator
Who are the founders of Adventris
Market Focus
Adventris primarily focuses on the biotechnology industry, specifically in cancer immunotherapy.
Competitors Overview
Adventris operates in the cancer immunotherapy market and faces competition from several notable companies:
-
BeiGene: Specializes in developing targeted and immune-oncology drugs against cancer. It has raised significant funding of $172 million, which allows for extensive research and development capabilities.
-
Moderna: Known for its mRNA-based therapeutics, Moderna has raised approximately $2.78 billion. This substantial funding supports its broad range of applications, including cancer treatment, giving it a strong market presence and innovative edge.
-
Incyte: Focuses on small molecules for treating various cancers and skin diseases. Incyte's established market presence and expertise in small molecule therapies provide it with a competitive advantage in the oncology space.
Compared to these competitors, Adventris has raised $125,000 in its seed round, which may limit its research and development capabilities and market reach. The significant funding and established presence of its competitors provide them with advantages in innovation and market penetration.
Investors
- Y Combinator
- Johns Hopkins Technology Ventures
- Refactor Capital
See something that needs updating? Suggest edits to this profile.